Good point, but Mesoblast did not mention anything in relation to the Pandemic in announcing the delay of trial results to the fourth quarter.
In hind site cannot understand why they wouldn't be more forthcoming on advising the market on such important announcements!
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-331
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
-0.015(1.30%) |
Mkt cap ! $1.295B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.15 | $1.14 | $841.5K | 737.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 60051 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 5 | 2 |
View Market Depth
| Last trade - 10.54am 22/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |